adamantane has been researched along with Ventricular Dysfunction, Left in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jiang, C; Li, X; Liang, G; Sa-Nguanmoo, P; Tanajak, P; Wang, X | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Kumfu, S; Lekawanvijit, S; Pongkan, W | 1 |
3 other study(ies) available for adamantane and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diabetic Cardiomyopathies; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Fibroblast Growth Factors; Gene Expression Regulation; Heart Rate; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mitochondria, Heart; Nitriles; Obesity; Prediabetic State; Pyrrolidines; Rats; Rats, Wistar; Recombinant Proteins; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Vildagliptin | 2017 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Heart Rate; Insulin Resistance; Intracellular Space; Male; Metformin; Mitochondria; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Wistar; Ventricular Dysfunction, Left; Vildagliptin | 2014 |
Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Enalapril; Fibrosis; Heart Rate; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction; Myocardium; Nitriles; Oxidative Stress; Pyrrolidines; Rats, Wistar; Recovery of Function; Signal Transduction; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling; Vildagliptin | 2015 |